This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Hoth options GWU's aprepitant patents for dermatological side effects of erlotinib
29 Aug 2019
Following a sponsored research agreement announced last month, Hoth Therapeutics Inc. signed a definitive agreement with George Washington University, gaining an exclusive option to the latter's patents (Nos. 9,474,761 and 9,687,493) related to methods of using aprepitant or other neurokinin-1 (NK-1) receptor antagonists for topical and/or systemic therapy to address dermatological-related side effects of erlotinib in cancer patients.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?